Mitsubishi Tanabe Pharma Corporation

Osaka University

Hiroaki Sawamoto

Norimitsu Hayashi

Osamu Sakurai

Kunio Saruta

Satoshi Obika

Kenji Morokuma

Ritsuo Imashiro

Hiroaki Shitama

Hidekazu Tsujishima

Shinji Kumagai

Eri Ooboki

Takashi Goi

Hiroyuki Furukawa

Eiji Kawanishi

Shuhei Yamakoshi

Yuuki Aral

Tomo Araki

Masayuki Utsugi

Yuuki Arai

Eri Oboki

The present invention provides a novel bridged artificial nucleic acid and an oligomer containing the same as a monomer. The present invention provides specifically a compound represented by general formula (I) (wherein each symbol is the same as defined in the specification) or salts thereof; as well as an oligonucleotide compound represented by general formula (I′) (wherein each symbol is the same as defined in the specification) or salts thereof.

Crosslinked artificial nucleic acid ALNA

A method for preparing a compound represented by general formula I: or a salt thereof includes a step of reacting a compound represented by formula II: with a reducing agent to cleave an oxazolidine ring fused to a cycle A'. The reducing agent includes at least one of phosphines, metal hydrides, or transition metal catalysts in the presence of hydrogen gas.

Bridged nucleic acid GuNA, method for producing same, and intermediate compound

The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CRor nitrogen atom; Ris hydrogen and the like; Ris alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.

Aromatic heterocyclic compound

This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof. 

Continuous arycyclic compound

Growing community of inventors

Osaka, Japan

Hiroaki Sawamoto